Overview
Orgenesis Inc., based in the United States, operates primarily within the biotechnology sector, focusing on the development of personalized therapies and closed-automation systems for cell and gene therapies. The company is at the forefront of advancing and commercializing such therapies with a particular emphasis on diabetes treatment and other serious diseases. A key project includes their proprietary "Point-of-Care" platform, designed to deliver personalized cell and gene therapies efficiently at the site of care. Orgenesis also collaborates with medical institutions and biotech firms to speed up regulatory approval processes and commercialization of these innovative therapies, thereby potentially transforming the treatment paradigm for chronic diseases. Through strategic partnerships and rigorous research and development, Orgenesis is committed to reducing costs and improving access to transformative medical treatments.
Basic Stats
The share price of Orgenesis Inc. as of October 18, 2024 is $2.11 / share.
The Factor Analysis chart (below right) shows a view of Orgenesis Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | |
| EV | |
| Shares Out. | 0.00 MM |
| Earnings Date | |
| EPS (TTM) | |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 3.93 |
| Short Shares Avail. | 0.15 MM |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | 10.22 |
| Beta | -0.59 |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | 0.00 |
| ROE | |
| ROIC | |
| CROIC | |
| OCROIC | |
| Implied Volatility | |
| Put/Call OI Ratio |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Orgenesis Inc. is $6.12. The forecasts range from a low of $6.06 to a high of $6.30. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Orgenesis Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2019-09-26 | Benchmark | Speculative Buy | Initiate | |
| 2023-03-22 | Benchmark | Buy | Reiterate | |
| 2023-06-14 | Benchmark | Speculative Buy | Speculative Buy | Reiterate |
